Literature DB >> 27667712

Emerging roles of p53 and other tumour-suppressor genes in immune regulation.

César Muñoz-Fontela1, Anna Mandinova2,3,4, Stuart A Aaronson5, Sam W Lee2,4.   

Abstract

Tumour-suppressor genes are indispensable for the maintenance of genomic integrity. Recently, several of these genes, including those encoding p53, PTEN, RB1 and ARF, have been implicated in immune responses and inflammatory diseases. In particular, the p53 tumour- suppressor pathway is involved in crucial aspects of tumour immunology and in homeostatic regulation of immune responses. Other studies have identified roles for p53 in various cellular processes, including metabolism and stem cell maintenance. Here, we discuss the emerging roles of p53 and other tumour-suppressor genes in tumour immunology, as well as in additional immunological settings, such as virus infection. This relatively unexplored area could yield important insights into the homeostatic control of immune cells in health and disease and facilitate the development of more effective immunotherapies. Consequently, tumour-suppressor genes are emerging as potential guardians of immune integrity.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27667712      PMCID: PMC5325695          DOI: 10.1038/nri.2016.99

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  191 in total

Review 1.  Divorcing ARF and p53: an unsettled case.

Authors:  Charles J Sherr
Journal:  Nat Rev Cancer       Date:  2006-08-17       Impact factor: 60.716

2.  AMP-activated protein kinase induces a p53-dependent metabolic checkpoint.

Authors:  Russell G Jones; David R Plas; Sara Kubek; Monica Buzzai; James Mu; Yang Xu; Morris J Birnbaum; Craig B Thompson
Journal:  Mol Cell       Date:  2005-04-29       Impact factor: 17.970

3.  CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer.

Authors:  Tomoe Higuchi; Dallas B Flies; Nicole A Marjon; Gina Mantia-Smaldone; Lukas Ronner; Phyllis A Gimotty; Sarah F Adams
Journal:  Cancer Immunol Res       Date:  2015-07-02       Impact factor: 11.151

Review 4.  Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.

Authors:  Padmanee Sharma; James P Allison
Journal:  Cell       Date:  2015-04-09       Impact factor: 41.582

Review 5.  Type I interferons in anticancer immunity.

Authors:  Laurence Zitvogel; Lorenzo Galluzzi; Oliver Kepp; Mark J Smyth; Guido Kroemer
Journal:  Nat Rev Immunol       Date:  2015-06-01       Impact factor: 53.106

Review 6.  Tailoring to RB: tumour suppressor status and therapeutic response.

Authors:  Erik S Knudsen; Karen E Knudsen
Journal:  Nat Rev Cancer       Date:  2008-09       Impact factor: 60.716

Review 7.  Interactions between the tumor suppressor p53 and immune responses.

Authors:  Daniel Menendez; Maria Shatz; Michael A Resnick
Journal:  Curr Opin Oncol       Date:  2013-01       Impact factor: 3.645

8.  p53 in the Myeloid Lineage Modulates an Inflammatory Microenvironment Limiting Initiation and Invasion of Intestinal Tumors.

Authors:  Xue-Yan He; Cong Xiang; Chen-Xi Zhang; Yin-Yin Xie; Lai Chen; Guo-Xin Zhang; Yi Lu; Geng Liu
Journal:  Cell Rep       Date:  2015-10-22       Impact factor: 9.423

9.  Leukocyte marker CD43 promotes cell growth in co-operation with β-catenin in non-hematopoietic cancer cells.

Authors:  Anna Balikova; Kersti Jääger; Janeli Viil; Toivo Maimets; Lilian Kadaja-Saarepuu
Journal:  Int J Oncol       Date:  2012-04-19       Impact factor: 5.650

10.  Brca2 deficiency leads to T cell loss and immune dysfunction.

Authors:  Jun-Hyeon Jeong; Areum Jo; Pilgu Park; Hyunsook Lee; Hae-Ock Lee
Journal:  Mol Cells       Date:  2015-02-04       Impact factor: 5.034

View more
  131 in total

1.  Ipr1 Regulation by Cyclic GMP-AMP Synthase/Interferon Regulatory Factor 3 and Modulation of Irgm1 Expression via p53.

Authors:  Fayang Liu; Hongni Xue; Jie Ke; Yongyan Wu; Kezhen Yao; Shuxin Liang; Aihua Xu; Yong Zhang
Journal:  Mol Cell Biol       Date:  2020-03-30       Impact factor: 4.272

2.  Myeloid PTEN promotes chemotherapy-induced NLRP3-inflammasome activation and antitumour immunity.

Authors:  Yi Huang; Huanyu Wang; Yize Hao; Hualong Lin; Menghao Dong; Jin Ye; Lei Song; Yunzhi Wang; Qingqing Li; Benjie Shan; Yizhou Jiang; Hongqi Li; Zhiming Shao; Guido Kroemer; Huafeng Zhang; Li Bai; Tengchuan Jin; Chao Wang; Yuting Ma; Yongping Cai; Chen Ding; Suling Liu; Yueyin Pan; Wei Jiang; Rongbin Zhou
Journal:  Nat Cell Biol       Date:  2020-05-04       Impact factor: 28.824

3.  MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment.

Authors:  Douglas D Fang; Qiuqiong Tang; Yanhui Kong; Qixin Wang; Jiaxing Gu; Xu Fang; Peng Zou; Tao Rong; Jingwen Wang; Dajun Yang; Yifan Zhai
Journal:  J Immunother Cancer       Date:  2019-11-28       Impact factor: 13.751

Review 4.  Epigenetic Mechanisms Dictating Eradication of Cancer by Natural Killer Cells.

Authors:  Suresh Bugide; Radoslav Janostiak; Narendra Wajapeyee
Journal:  Trends Cancer       Date:  2018-07-03

5.  Regulation of autoimmune disease by the E3 ubiquitin ligase Itch.

Authors:  Emily K Moser; Paula M Oliver
Journal:  Cell Immunol       Date:  2019-04-05       Impact factor: 4.868

Review 6.  The Photomodulation Activity of Metformin Against Oral Microbiome.

Authors:  Shima Afrasiabi; Maryam Pourhajibagher; Abbas Bahador
Journal:  J Lasers Med Sci       Date:  2019-07-06

Review 7.  Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy.

Authors:  Daixi Ren; Yuze Hua; Boyao Yu; Xin Ye; Ziheng He; Chunwei Li; Jie Wang; Yongzhen Mo; Xiaoxu Wei; Yunhua Chen; Yujuan Zhou; Qianjin Liao; Hui Wang; Bo Xiang; Ming Zhou; Xiaoling Li; Guiyuan Li; Yong Li; Zhaoyang Zeng; Wei Xiong
Journal:  Mol Cancer       Date:  2020-01-30       Impact factor: 27.401

Review 8.  The p53 Saga: Early Steps in the Development of Tumor Immunotherapy.

Authors:  Albert B DeLeo; Ettore Appella
Journal:  J Immunol       Date:  2020-05-01       Impact factor: 5.422

9.  The Nonstructural NS1 Protein of Influenza Viruses Modulates TP53 Splicing through Host Factor CPSF4.

Authors:  Manuel Rosa-Calatrava; Olivier Terrier; Julia Dubois; Aurélien Traversier; Thomas Julien; Blandine Padey; Bruno Lina; Jean-Christophe Bourdon; Virginie Marcel; Guy Boivin
Journal:  J Virol       Date:  2019-03-21       Impact factor: 5.103

10.  Transforming the prostatic tumor microenvironment with oncolytic virotherapy.

Authors:  Matthew J Atherton; Kyle B Stephenson; Fanny Tzelepis; David Bakhshinyan; Jake K Nikota; Hwan Hee Son; Anna Jirovec; Charles Lefebvre; Anna Dvorkin-Gheva; Ali A Ashkar; Yonghong Wan; David F Stojdl; Eric C Belanger; Rodney H Breau; John C Bell; Fred Saad; Sheila K Singh; Jean-Simone Diallo; Brian D Lichty
Journal:  Oncoimmunology       Date:  2018-03-27       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.